Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AT-752 in Healthy Subjects
NCT04722627Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Nov 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of arbemnifosbuvir in dengue fever (14 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events at Day 12, Pharmacokinetics of AT-752 at Day 7 and 1 more. Started Mar 2021; status: completed.
02
Drugs
arbemnifosbuvir
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT04722627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722627.